Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
Pilot Studies Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
Wright State University
48 participants
Feb 27, 2024
INTERVENTIONAL
Conditions
Summary
Rosacea is a common skin condition associated with easy blushing and red face; many patients with rosacea react to sunlight with increased redness. The purpose of this study is to determine if the use of a topical medication will help reduce sunlight induced redness and irritation in patients with rosacea.
Eligibility
Inclusion Criteria3
- Fitzpatrick Skin Type I - IIII
- Self-identified rosacea or no history of flushing/blushing for controls
- Able to provide medical history and list of medications -- control subjects will not be allowed to take medications that are known to be photosensitizers.
Exclusion Criteria6
- Using imipramine, amitriptyline or any other tricyclic antidepressant (oral or topical)
- Using topical anti-inflammatory (within 1 week) or systemic agents (e.g. prednisone)
- Large tattoos in the designated testing areas
- Tanning bed use within last 3 months
- Photodynamic Therapy or UCB treatments in past 3 months
- Female Subjects: pregnant or nursing
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
4% imipramine
4% amitriptyline
0.1ml propylene glycol
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06312813